Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator

Journal of Oncology Practice

Volumn 8, Issue 3, 2012, Pages 144-149

  Wills, Shannon ^a   Ravipati, Anita ^a   Venuturumilli, Padmaja ^a   Kresge, Cynthia ^a   Folkerd, Elizabeth ^a   Dowsett, Mitch ^a   Hayes, Daniel F ^a   Decker, David A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; ESTRADIOL; EXEMESTANE; LETROZOLE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; AGED; ARTICLE; ATROPHIC VAGINITIS; BLOOD SAMPLING; CANCER SURVIVOR; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ESTRADIOL BLOOD LEVEL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; ESTROGEN THERAPY; FEMALE; HIGH RISK PATIENT; HUMAN; LOADING DRUG DOSE; POSTMENOPAUSE; RADIOIMMUNOASSAY; TABLET;

EID: 84867904099     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000352     Document Type: Article

References (40)

1. Early Breast Cancer Trialists Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-717, 2005
2. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006
3. Smith IE, Dowsett M: Aromatase inhibitors in breast cancer. N Engl J Med 348:2431-2442, 2003 (Pubitemid 36682823)
4. Dugal R, Hesla K, Sørdal T, et al: Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy. Acta Obstet Gynecol Scand 79:293-297, 2000 (Pubitemid 30156501)
5. Fallowfield L, Cella D, Cuzick J, et al: Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial. J Clin Oncol 22:4261-4271, 2004 (Pubitemid 41185147)
6. Ferretti G, Bria E, Giannarelli D, et al: Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: A pooled analysis of the randomised trials. Br J Cancer 94:1789-1796, 2006 (Pubitemid 43882568)
7. Ganz PA, Greendale GA, Petersen L, et al: Managing menopausal symptoms in breast cancer survivors: Results of a randomized controlled trial. J Natl Cancer Inst 92: 1054-64, 2000 (Pubitemid 30618024)
8. Kendall A, Dowsett M, Folkerd E, et al: Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors. Ann Oncol 17:584-587, 2006
9. Notelovitz M: Urogenital aging: Solutions in clinical practice. Int J Gynaecol Obstet 59:S35-S39, 1997 (suppl 1)
10. Stenberg A, Heimer G, Ulmsten U: The prevalence of urogenital symptoms in postmenopausal women. Maturitas 22:S17-S20, 1995 (suppl) (Pubitemid 26021027)
11. Cella D, Fallowfield L, Barker P, et al: Quality of life of postmenopausal women in the ATAC ("Arimidex," tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100:273-284, 2006 (Pubitemid 44707921)
12. Mattsson LA, Cullberg G, Eriksson O, et al: Vaginal administration of low-dose oestradiol- effects on the endometrium and vaginal cytology. Maturitas 11:217-222, 1989 (Pubitemid 19249682)
13. Akrivis Ch, Varras M, Thodos A, et al: Action of 25 microg 17beta-oestradiol vaginal tablets in the treatment of vaginal atrophy in Greek postmenopausal women; clinical study. Clin Exp Obstet Gynecol 30:229-234, 2003 (Pubitemid 37456323)
14. Suckling J, Lethaby A, Kennedy R: Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 4:CD001500, 2006
15. Castelo-Branco C, Cancelo MJ, Villero J, et al: Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas 52:S46-S52, 2005 (suppl 1)
16. Rioux JE, Devlin C, Gelfand MM, et al: 17beta-estradiol vaginal tablet versus conjugated equine estrogen vaginal cream to relieve menopausal atrophic vaginitis. Menopause 7:156-161, 2000 (Pubitemid 30249896)
17. Weisberg E, Ayton R, Darling G, et al: Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric 8:83-92, 2005 (Pubitemid 40675125)
18. Estrogen replacement therapy in breast cancer survivors. A time for change. Breast Cancer Committees of the Eastern Cooperative Oncology Group. JAMA 273:540-545, 1994
19. Holmberg L, Anderson H: HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: Trial stopped. Lancet 363:453-455, 2004 (Pubitemid 38210063)
20. Baum M, Budzar AU, Cuzick J, et al: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002 (Pubitemid 34694019)
21. Lynch C: Vaginal estrogen therapy for the treatment of atrophic vaginitis. J Womens Health 18:1595-1606, 2009
22. Ballagh SA: Vaginal rings for menopausal symptom relief. Drugs Aging 21:757-766, 2004
23. Howard G, Wills S, Kresge C, et al: The effects of vaginal estrogens on plasma estradiol levels in women taking aromatase inhibitors. Breast Cancer Res Treat 106:3085a, 2007 (suppl 1)
24. Dowsett M, Goss PE, Powles TJ, et al: Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: Optimization of therapeutic dose and route. Cancer Res 47: 1957-61, 1987 (Pubitemid 17056706)
25. Beattie MS, Costantino JP, Cummings SR, et al: Endogenous sex hormones, breast cancer risk, and tamoxifen response: An ancillary study in the NSABP breast cancer prevention trial (P-1). J Natl Cancer Inst 98:110-115, 2006 (Pubitemid 43159965)
26. Cummings SR, Duong T, Kenyon E: Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 287:216-220, 2002 (Pubitemid 34251947)
27. Kostoglou-Athanassiou I, Ntalles K, Gogas J, et al: Sex hormones in postmenopausal women with breast cancer on tamoxifen. Horm Res 47:116-120, 1997 (Pubitemid 27105334)
28. Boccardo F, Guarneri D, Rubagotti A, et al: Endocrine effects of tamoxifen in postmenopausal breast cancer patients. Tumori 70:61-68, 1984 (Pubitemid 14173637)
29. Naessen T, Rodriguez-Macias K, Lithell H: Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab 86:2757-2762, 2001 (Pubitemid 32545735)
30. Hadji P: Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73:156-166, 2010
31. Partridge AH, Wang PS, Winer EP, et al: Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602-606, 2003 (Pubitemid 46621892)
32. Chlebowski RT, Geller ML: Adherence to endocrine therapy for breast cancer. Oncology 71:1-9, 2006
33. Atkins L, Fallowfield L: Intentional and non-intentional non-adherence to medication amongst breast cancer patients. Eur J Cancer 42:2271-2276, 2006 (Pubitemid 44307611)
34. Caswell M, Kane M: Comparison of the moisturization efficacy of two vaginal moisturizers: Pectin versus polycarbophil technologies. J Cosmet Sci 53:81-87, 2002
35. Loprinzi CL, Abu-Ghazaleh S, Sloan JA, et al: Phase III randomized double-blind study to evaluate the efficacy of a polycarbophil-based vaginal moisturizer in women with breast cancer. J Clin Oncol 15:969-973, 1997 (Pubitemid 27106279)
36. Hayes DF: Clinical practice. Follow-up of patients with early breast cancer. N Engl J Med 356:2505-2513, 2007
37. Pruthi S, Simon JA, Early AP: Current overview of the management of urogenital atrophy in women with breast cancer. Breast J 17:403-408, 2010
38. Eugster-Hausmann M, Waitzinger J, Lehnick D: Minimized estradiol absorption with ultra-low-dose 10 microg 17B-estradiol vaginal tablets. Climacteric 13:219-227, 2010
39. Bachmann G, Lobo RA, Gut R, et al: Efficacy of low-dose estradiol vaginal tablets. Obstet Gynecol 111:67-76, 2008
40. Memorial Sloan-Kettering Cancer Center Clinical Trials. Serum estradiol levels in postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors and vaginal estrogens. NCT00984300. http://www.ClinicalTrials.gov